The impact of oral contraceptives and metformin on anti-Müllerian hormone serum levels in women with polycystic ovary syndrome and biochemical hyperandrogenemia
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To assess the impact of metformin and of two different oral contraceptives (OCs) containing cyproterone acetate and drospirenone, on serum anti-Müllerian hormone (AMH) levels, in a cohort of women with polycystic ovary syndrome (PCOS) with hyperandrogenism. DESIGN: Prospective randomised study. SETTING: Division of Endocrinology and Human Reproduction, Aristotle University of Thessaloniki. PATIENTS: Forty-five (45) women with PCOS diagnosed according to the criteria proposed in 1990 by the NIH. INTERVENTIONS: Women with PCOS were randomised into three groups, all treated for 6 months: Group A received an OC containing 35 μg ethinylestradiol plus 2 mg cyproterone acetate, Group B received an OC containing 30 μg ethinylestradiol plus 3 mg drospirenone and Group C received metformin 850 mg × 2. Main outcome measure(s). Anti-Müllerian hormone levels were measured by a specific ELISA. RESULTS: AMH was significantly decreased under treatment with 35 μg ethinylestradiol plus 2 mg cyproterone acetate (p = 0.002 at 3 months and p < 0.001 at 6 months). Treatment with 30 μg ethinylestradiol plus 3 mg drospirenone, and treatment with metformin 850 mg × 2 did not significantly affect serum AMH levels. AMH was significantly decreased under OCs treatment compared to metformin 850 mg × 2 (p = 0.005). CONCLUSION(S): AMH serum levels were significantly decreased under treatment with 35 μg ethinylestradiol plus 2 mg cyproterone acetate, due to decrease in androgens and suppression of gonadotropins.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group (2004) · Human Reproduction · doi:10.1093/humrep/deh098 · Cited by 6,138
Profound Peripheral Insulin Resistance, Independent of Obesity, in Polycystic Ovary Syndrome
Dunaif, A., Segal, K. R., Futterweit, W., & Dobrjansky, A. (1989) · Diabetes · doi:10.2337/diab.38.9.1165 · Cited by 1,967
Norman, R. J., Dewailly, D., Legro, R. S., & Hickey, T. E. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61345-2 · Cited by 1,360 · cited 1×
“PCOS is characterized by hyperandrogenism (hirsutism and/or biochemical hyperandrogenemia) and oligo/anovulation, and is also highly associated with obesity and insulin resistance (IR) [3].”
BackgroundPigny, P., Merlen, E., Robert, Y., Cortet-Rudelli, C., Decanter, C., Jonard, S., & Dewailly, D. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030727 · Cited by 709 · cited 1×
“Since intra-ovarian androgens are also responsible for defective follicular selection and follicular arrest, it has been proposed that the intraovarian hyperandrogenism by increasing the AMH intraovarian level could exert an inhibiting effect on the selection process [8].”
BackgroundCarmina, E., & Lobo, R. A. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.6.5803 · Cited by 528
Metformin for the treatment of the polycystic ovary syndrome
Nestler, J. E. (2008) · New England Journal of Medicine · doi:10.1056/nejmct0707092 · Cited by 313 · cited 1×
“On the contrary, metformin improves insulin sensitivity and, in addition, may decrease circulating androgen levels and may improve menstrual cyclicity, thus addressing the traditional goals of long-term treatment [20].”
BackgroundNader, S., & Diamanti-Kandarakis, E. (2007) · Human Reproduction · doi:10.1093/humrep/del407 · Cited by 109 · cited 1×
“Treatment with OCs is known to normalise menstrual function and to ameliorate hirsutism and acne, while the effects on IR are controversial [12].”
BackgroundSelf-citationWu, J., Zhu, Y., Jiang, Y., & Cao, Y. (2008) · Gynecological Endocrinology · doi:10.1080/09513590802217027 · Cited by 52
Cited by
Banaszewska, B., Wrotyńska-Barczyńska, J., Spaczynski, R. Z., Pawelczyk, L., & Duleba, A. J. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-1858 · Cited by 173
Fraison, E., Kostova, E., Moran, L. J., Bilal, S., Ee, C. C., Venetis, C., & Costello, M. F. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005552.pub3 · Cited by 94
Melin, J., Forslund, M., Alesi, S., Piltonen, T., Romualdi, D., Spritzer, P. M., Tay, C. T., Pena, A., Witchel, S. F., Mousa, A., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad465 · Cited by 78
Luque-Ramírez, M., Nattero-Chávez, L., Ortiz Flores, A. E., & Escobar-Morreale, H. F. (2018) · Human Reproduction Update · doi:10.1093/humupd/dmx039 · Cited by 62
Vosnakis, C., Georgopoulos, N. A., Rousso, D., Mavromatidis, G., Katsikis, I., Roupas, N. D., Mamali, I., & Panidis, D. (2013) · Gynecological Endocrinology · doi:10.3109/09513590.2012.736557 · Cited by 48
Self-citation
Metadata
- Authors
- Panidis, D., Georgopoulos, N. A., Piouka, A., Katsikis, I., Saltamavros, A. D., Decavalas, G., & Diamanti-Kandarakis, E.
- Venue
- Gynecological Endocrinology
- Publisher
- Informa UK Limited
- Published
- 2010-09-14
- Volume
- 27
- Issue
- 8
- Pages
- 587-592
- ISSN
- 0951-3590 (ISSN-L)
- 1473-0766
- OpenAlex
- W2129013969
- Cited by
- 71
- References
- 8
- FWCI
- 4.56
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The impact of oral contraceptives and metformin on anti-Müllerian hormone serum levels in women with polycystic ovary syndrome and biochemical hyperandrogenemia. https://app.cochat.ai/papers/10.3109/09513590.2010.507283
- The paper
- Panidis, D., Georgopoulos, N. A., Piouka, A., Katsikis, I., Saltamavros, A. D., Decavalas, G., & Diamanti-Kandarakis, E. (2011). The impact of oral contraceptives and metformin on anti-Müllerian hormone serum levels in women with polycystic ovary syndrome and biochemical hyperandrogenemia. Gynecological Endocrinology. https://doi.org/10.3109/09513590.2010.507283
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.